Russell Investments Group Ltd. Buys 176,078 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Russell Investments Group Ltd. significantly increased its holdings in Elanco Animal Health by 695.7%, owning 201,389 shares valued at approximately $2.12 million after purchasing an additional 176,078 shares in the first quarter.
• Several other institutional investors, including Allworth Financial LP and Parallel Advisors LLC, also raised their stakes in Elanco Animal Health, contributing to an overall institutional ownership of 97.48% of the company's stock.
• Elanco Animal Health reported $1.24 billion in revenue and earnings per share of $0.26, surpassing analysts' expectations in its most recent quarterly earnings report.

Russell Investments Group Ltd. lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 695.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 201,389 shares of the company's stock after acquiring an additional 176,078 shares during the period. Russell Investments Group Ltd.'s holdings in Elanco Animal Health were worth $2,115,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Yousif Capital Management LLC acquired a new position in Elanco Animal Health during the 1st quarter valued at approximately $119,000. Wealth Enhancement Advisory Services LLC acquired a new position in Elanco Animal Health during the 1st quarter valued at approximately $111,000. SG Americas Securities LLC acquired a new position in Elanco Animal Health during the 1st quarter valued at approximately $891,000. GAMMA Investing LLC boosted its position in Elanco Animal Health by 1,743.8% during the 1st quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock valued at $130,000 after purchasing an additional 11,718 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Elanco Animal Health by 127.5% in the 4th quarter. Ameriprise Financial Inc. now owns 97,373 shares of the company's stock valued at $1,179,000 after acquiring an additional 54,581 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Down 0.4%

ELAN traded down $0.08 during midday trading on Friday, hitting $18.38. 71,268,743 shares of the company's stock traded hands, compared to its average volume of 11,024,990. The company has a market cap of $9.13 billion, a PE ratio of 21.37, a price-to-earnings-growth ratio of 3.41 and a beta of 1.62. The stock's fifty day simple moving average is $15.55 and its 200-day simple moving average is $12.71. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.87.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. During the same quarter in the prior year, the business earned $0.30 earnings per share. The company's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ELAN shares. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research report on Thursday, July 17th. Zacks Research downgraded Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. UBS Group upped their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Finally, Piper Sandler upped their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.